Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Its lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases. The company is based in Norwood, Massachusetts.
